PUBLISHER: The Business Research Company | PRODUCT CODE: 1670286
PUBLISHER: The Business Research Company | PRODUCT CODE: 1670286
Malaria treatment encompasses the medical interventions and procedures aimed at diagnosing, managing, and curing malaria, a potentially life-threatening mosquito-borne disease caused by the Plasmodium parasite.
The primary components of malaria treatment include prescription medications, vaccines, diagnostic tests, and other therapeutic approaches. Prescription medications are pharmaceuticals that require a valid prescription from a healthcare professional. In the context of malaria treatment, these drugs are essential for providing targeted and regulated therapy to combat the infection. They can be administered through oral, parenteral, and intravenous routes and are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. These channels serve hospitals, specialty clinics, home care settings, and other end users, ensuring a comprehensive reach for malaria treatment options.
The malaria treatment market research report is one of a series of new reports from The Business Research Company that provides malaria treatment market statistics, including malaria treatment industry global market size, regional shares, competitors with a malaria treatment market share, detailed malaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malaria treatment industry. This malaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The malaria treatment market size has grown steadily in recent years. It will grow from $1.55 billion in 2024 to $1.62 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to the discovery of effective drugs, vector control efforts, global health initiatives, scientific research, and health infrastructure development
The malaria treatment market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to drug resistance monitoring, climate change impact, precision medicine and genomic approaches, healthcare financing reforms, and integration of digital health solutions. Major trends in the forecast period include epidemiological surveillance enhancement, alternative medicine integration, malaria vaccine development, data-driven treatment programs, and education and training programs.
The rising incidence of malaria is anticipated to drive the growth of the malaria treatment market in the future. Malaria is a potentially life-threatening disease transmitted by mosquitoes and caused by the Plasmodium parasite, characterized by recurring fevers and flu-like symptoms. Factors such as poverty, limited access to healthcare, climate change, insufficient malaria control measures, and drug resistance have contributed to this increase. Effective malaria treatment is essential for managing and curing infections caused by the Plasmodium parasite. For instance, the World Malaria Report 2023 published by the World Health Organization, a Switzerland-based intergovernmental organization, indicated that global malaria cases reached 249 million in 2022, an increase of five million compared to 2021. Therefore, the high incidence of malaria is driving the growth of the malaria treatment market.
The rise in healthcare spending is projected to fuel the growth of the malaria treatment market in the coming years. Healthcare spending refers to the total financial resources allocated to the healthcare sector in a specific region, country, or organization. Investment in malaria treatment is essential for effectively managing the disease and preventing its spread, ensuring timely access to diagnosis, antimalarial medications, and preventive measures. For example, in July 2024, the American Medical Association, a US-based professional association and lobbying group for physicians and medical students, reported that health spending in the United States increased by 4.1% in 2022, reaching $4.5 trillion or $13,493 per capita. Therefore, the increase in healthcare spending is driving the growth of the malaria treatment market.
Key players in the malaria treatment market are advancing technologies like the VERV Program to improve the efficiency and effectiveness of malaria diagnostics and treatments, with the goal of alleviating the disease burden in endemic regions. The VERV Program is an initiative from the Environmental Protection Agency (EPA) aimed at fostering the development of new mosquito control products to combat diseases such as malaria by providing expedited review vouchers for product registration. For example, in December 2023, the EPA, a US government agency, launched the Vector Expedited Review Voucher (VERV) Program. This program is designed to offer financial incentives to companies that create new pesticides specifically aimed at mosquito populations that have developed resistance to traditional insecticides. It will also streamline the registration process for eligible products, accelerating their availability in the market.
Leading companies in the malaria treatment market are prioritizing the development of vaccine rollouts to bolster prevention efforts and alleviate the global burden of malaria. A vaccine rollout involves the large-scale distribution and administration of vaccines to a population. For example, in July 2024, Gavi, a vaccine alliance based in Sweden, initiated the rollout of the R21 malaria vaccine. This vaccine is anticipated to significantly lower the incidence of malaria cases among children under five years old. The R21 malaria vaccine marks a crucial advancement in public health initiatives aimed at fighting malaria in children, with the expectation that it will lead to a notable decrease in both the disease burden and mortality rates associated with this preventable illness.
In November 2022, Novartis AG, a Switzerland-based pharmaceutical and healthcare company, joined forces with Medicines for Malaria Venture to conduct phase III clinical trials for a novel ganaplacide and lumefantrine-SDF medication combination targeting malaria in both adults and children. Medicines for Malaria Venture (MMV), as a Switzerland-based non-profit organization focused on antimalarial drug research and development, underscores the collaborative efforts within the industry to advance malaria treatment solutions.
Major companies operating in the malaria treatment market include Pfizer Inc., Merck & Co., Johnson & Johnson, Roche Holding AG, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca Plc, GlaxoSmithKline PLC., Takeda Pharmaceutical Company Limited, Sumitomo Chemical Co. Ltd., Viatris Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Serum Institute of India, Cipla Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., Zydus Lifesciences Limited, Ipca Laboratories Ltd., Chongqing Holley Pharmaceutical Co. Ltd., Zydus Lifesciences Ltd., Medicines Sans Frontieres, Strides Pharma Science Limited, Swiss Tropical and Public Health Institute (Swiss TPH), AdvaCare Pharma USA LLC, Medicines for Malaria Venture (MMV), VLP Therapeutics LLC, Actiza Pharmaceutical Private Limited
Middle East and Africa was the largest region in the malaria treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malaria treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the malaria treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The malaria treatment market consists of sales of antimicrobial medications, antimalarial drugs, antipyretics, intravenous fluids, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Malaria Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on malaria treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for malaria treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The malaria treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.